MarketBeat
18 Aug 2026, 08:02 UTC · 2h ago
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
18 Aug 2026, 08:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Tenaya expects to provide regulatory and development updates for TN-201, TN-401, and TN-301 in the fourth quarter. — Regulatory updates for three separate candidates in one quarter create a high-volatility catalyst window for the stock.
+0.60TN-401 has shown PVC reductions of 60% to 67%, exceeding the 50% threshold characterized by key opinion leaders as clinically meaningful. — Direct evidence that a lead candidate is hitting efficacy benchmarks increases the probability of clinical success.
+0.50Tenaya's cash runway extends through Q3 next year, but excludes costs for potential pivotal studies for TN-401 or Phase 2 trials for TN-301. — The explicit exclusion of major trial costs suggests a high likelihood of near-term dilution or the need for financing.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The company is returning focus to TN-301, with Phase 2 plans to be outlined in Q4 and a study start targeted for H2 next year. — Diversifying the pipeline back into small molecules reduces binary risk associated with gene therapy alone.
+0.30Tenaya's collaboration with Alnylam includes a $10 million upfront payment and over $1 billion in potential milestone payments. — While the milestones are long-term, the partnership provides immediate validation and non-dilutive funding.
+0.20Which stocks this story touches
Positive updates on multiple drug candidates (TN-201, TN-401, TN-301) showing efficacy and safety, alongside a high-value collaboration with Alnylam.
Positive mention regarding a strategic collaboration to identify novel genetic targets in cardiology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
17h ago
